WO1990013653A1 - Fusion proteins containing n-terminal fragments of human serum albumin - Google Patents
Fusion proteins containing n-terminal fragments of human serum albumin Download PDFInfo
- Publication number
- WO1990013653A1 WO1990013653A1 PCT/GB1990/000650 GB9000650W WO9013653A1 WO 1990013653 A1 WO1990013653 A1 WO 1990013653A1 GB 9000650 W GB9000650 W GB 9000650W WO 9013653 A1 WO9013653 A1 WO 9013653A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hsa
- variant
- terminal
- fusion polypeptide
- fibronectin
- Prior art date
Links
- 102000008100 Human Serum Albumin Human genes 0.000 title description 64
- 108091006905 Human Serum Albumin Proteins 0.000 title description 64
- 102000037865 fusion proteins Human genes 0.000 title description 6
- 108020001507 fusion proteins Proteins 0.000 title description 6
- 210000004898 n-terminal fragment Anatomy 0.000 title description 3
- 229920001184 polypeptide Polymers 0.000 claims abstract description 42
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 42
- 230000004927 fusion Effects 0.000 claims abstract description 24
- 108010067306 Fibronectins Proteins 0.000 claims abstract description 17
- 102000016359 Fibronectins Human genes 0.000 claims abstract description 17
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 claims abstract description 13
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 10
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 5
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 5
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 3
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 3
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 229940034998 human von willebrand factor Drugs 0.000 claims 1
- 230000028327 secretion Effects 0.000 abstract description 10
- 125000000729 N-terminal amino-acid group Chemical group 0.000 abstract 1
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 26
- 229940024606 amino acid Drugs 0.000 description 26
- 150000001413 amino acids Chemical group 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 24
- 108091034117 Oligonucleotide Proteins 0.000 description 23
- 239000012634 fragment Substances 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 18
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 15
- 108020004705 Codon Proteins 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 108010014173 Factor X Proteins 0.000 description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241001515965 unidentified phage Species 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- PMKKIDFHWBBGDA-UHFFFAOYSA-N 2-(2,5-dioxopyrrol-1-yl)ethyl methanesulfonate Chemical compound CS(=O)(=O)OCCN1C(=O)C=CC1=O PMKKIDFHWBBGDA-UHFFFAOYSA-N 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 101000892431 Proteus hauseri Type II restriction enzyme PvuII Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001659 chemokinetic effect Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 101150047627 pgk gene Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Definitions
- the present invention relates to fusion polypeptides where two individual polypeptides or parts thereof are fused to form a single amino acid chain. Such fusion may arise from the expression of a single continuous coding sequence formed by recombinant DNA techniques.
- Fusion polypeptides are known, for example those where a polypeptide which is the ultimately desired product of the process is expressed with an N-terminal "leader sequence" which encourages or allows secretion of the polypeptide from the cell.
- leader sequence An example is disclosed in EP-A-116 201 (Chiron) .
- HSA Human serum albumin
- EP-A-147 198 discloses its expression in a transformed host, in this case yeast.
- EP-A-322 094 discloses N-terminal fragments of HSA, namely those consisting of residues 1-n where n is 369 to 419, which have therapeutic utility.
- the application also mentions the possibility of fusing the C-terminal residue of such molecules to other, unnamed, polypeptides.
- One aspect of the present invention provides a fusion polypeptide comprising, as at least part of the N-terminal portion thereof, an N-terminal portion of HSA or a variant thereof and, as at least part of the C-terminal portion thereof, another polypeptide except that, when the said N- terminal portion of HSA is the 1-n portion where n is 369 to 419 or a variant thereof then the said polypeptide is (a) the 585 to 1578 portion of human fibronectin or a variant thereof, (b) the 1 to 368 portion of CD4 or a variant thereof, (c) platelet derived growth factor, or a variant thereof, (d) transforming growth factor, or a variant thereof, (e) the 1-261 portion of mature human plasma fibronectin or a variant thereof, (f) the 278-578 portion of mature human plasma fibronectin or a variant thereof, (g) the 1-272 portion of mature human von illebrand's Factor or a variant thereof, or (h) alpha-1-antitryp
- the N-terminal portion of HSA is preferably the said 1-n portion, the 1-177 portion (up to and including the cysteine), the 1-200 portion (up to but excluding the cysteine) or a portion intermediate 1-177 and 1-200.
- HSA human serum albumin
- variants are intended to include (but not necessarily to be restricted to) minor artificial variations in sequence (such as molecules lacking one or a few residues, having conservative substitutions or minor insertions of residues, or having minor variations of amino acid structure).
- polypeptides which have 80%, preferably 85%, 90%, 95% or 99%, homology with HSA are deemed to be "variants”.
- variants are physiologically equivalent to HSA; that is to say, variants preferably share at least one pharmacological utility with HSA.
- any putative variant which is to be used pharmacologically should be non-immunogenic in the animal (especially human) being treated.
- Conservative substitutions are those where one or more amino acids are substituted for others having similar properties such that one skilled in the art of polypeptide chemistry would expect at least the secondary structure, and preferably the tertiary structure, of the polypeptide to be substantially unchanged.
- typical such substitutions include asparagine for glutamine, serine for asparagine and arginine for lysine.
- Variants may alternatively, or as well, lack up to ten (preferably only one or two) intermediate amino acid residues (ie not at the termini of the said N-terminal portion of HSA) in comparison with the corresponding portion of natural HSA; preferably any such omissions occur in the 100 to 369 portion of the molecule (relative to mature HSA itself) (if present).
- amino acids may be added, again in the 100 to 369 portion for preference (if present).
- physiologically functional equivalents also encompasses larger molecules comprising the said sequence plus a further sequence at the N-terminal (for example, pro-HSA, pre-pro-HSA and met-HSA) .
- the said "another polypeptide" in the fusion compounds of the invention cannot be the remaining portion of HSA, since otherwise the -whole polypeptide would be HSA, which would not then be a "fusion polypeptide”.
- the non-HSA portion is one of the said (a) to (h) entities.
- the 1 to 368 portion of CD4 represents the first four disulphide-linked immunoglobulin-like domains of the human T lymphocyte CD4 protein, the gene for and amino acid sequence of which are disclosed in D. Smith et al (1987) Science 328, 1704-1707. It is used to combat HIV infections.
- PDGF platelet-derived growth factor
- TGF- ⁇ transforming growth factors ⁇
- a cDNA sequence for the 1-261 portion of Fn was disclosed in EP-A-207 751 (obtained from plasmid pFH6 with endonuclease PvuII). This portion binds fibrin and can be used to direct fused compounds to blood clots.
- Variants of alpha-1-antitrypsin include those disclosed by Rosenburg et al (1984) Nature 312, 77-80.
- the present invention includes the Pittsburgh variant (Met ⁇ 5 ⁇ is mutated to Arg) and the variant where ro- ⁇ 57 and are mutated to alanine and arginine respectively. These compounds are useful in the treatment of septic shock and lung disorders.
- Variants of the non-HSA portion of the polypeptides of the invention include variations as discussed above in relation to the HSA portion, including those with conservative amino acid substitutions, and also homologues from other species.
- the fusion polypeptides of the invention may have N- ter inal amino acids which extend beyond the portion corresponding to the N-terminal portion of HSA.
- pre-, pro-, or pre- pro sequences may be added thereto, for example the yeast alpha-factor leader sequence.
- the fused leader portions of WO 90/01063 may be used.
- the polypeptide which is fused to the HSA portion may be a naturally-occurring polypeptide, a fragment thereof or a novel polypeptide, including a fusion polypeptide.
- a fragment of fibronectin is fused to the HSA portion via a 4 amino acid linker.
- the amino terminal portion of the HSA molecule is so structured as to favour particularly efficient translocation and export of the fusion compounds of the invention in eukaryotic cells.
- a second aspect of the invention provides a • transformed host having a nucleotide sequence so arranged as to express a fusion polypeptide as described above.
- “so arranged” we mean, for example, that the nucleotide sequence is in correct reading frame with an appropriate RNA polymerase binding site and translation start sequence and is under the control of a suitable promoter.
- the promoter may be homologous with or heterologous to the host.
- Downstream (3') regulatory sequences may be included if desired, as is known.
- the host is preferably yeast (for example Saccharomyces spp. , e.g. S. cerevisiae; Kluyveromyces spp., e.g. K.
- lactis Pichia spp.; or Schizosaccharomyces spp., e.g. S. pombe
- suitable host such as E. coli, B. subtilis, Asperqillus spp., mammalian cells, plant cells or insect cells.
- a third aspect of the invention provides a process for preparing a fusion polypeptide according to the first aspect of the invention by cultivation of a transformed host according to the second aspect of the invention, followed by separation of the fusion polypeptide in a useful form.
- a fourth aspect of the invention provides therapeutic methods of treatment of the human or other animal body comprising administration of such a fusion polypeptide.
- the fusion polypeptides of the present invention wherein the C-terminal portion is Fn 585-1578 can be used for wound healing applications as biosynthesised, especially where the hybrid human protein will be topically applied.
- the portion representing amino acids 585 to 1578 of human fibronectin can if desired be recovered from the fusion protein by preceding the first amino acid of the fibronectin portion by amino acids comprising a factor X cleavage site. After isolation of the fusion protein from culture supernatant, the desired molecule is released by factor X cleavage and purified by suitable chromatography (e.g. ion-exchange chromatography) .
- suitable chromatography e.g. ion-exchange chromatography
- Other sites providing for enzymatic or chemical cleavage can be provided, either by appropriate juxtaposition of the N-terminal and C-terminal portions or by the insertion therebetween of an appropriate linker.
- At least some of the fusion polypeptides of the invention also have an increased half-life in the blood and therefore have advantages and therapeutic utilities themselves, namely the therapeutic utility of the non-HSA portion of the molecule.
- the compound will normally be administered as a one-off dose or only a few doses over a short period, rather than over a long period, and therefore the compounds are less likely to cause an immune response.
- DNA sequences encoding portions of human serum albumin used in the construction of the following molecules are derived from the plas ids mH0B12 and pDBD2 (EP-A-322 094, Delta Biotechnology Ltd, relevant portions of which are reproduced below) or by synthesis of oligonucleotides equivalent to parts of this sequence.
- DNA sequences encoding portions of human fibronectin are derived from the plasmid pFHDELl, or by synthesis of oligonucleotides equivalent to parts of this sequence.
- Plasmid pFHDELl which contains the complete human cDNA encoding plasma fibronectin, was obtained by ligation of DNA derived from plasmids pFH6, 16, 54, 154 and 1 (EP-A-207 751; Delta Biotechnology Ltd) .
- This DNA represents an mRNA variant which does not contain the 'ED' sequence and had an 89-amino acid variant of the III-CS region (R.J. Owens, A.R. Kornblihtt and F.E. Baralle (1986) Oxford Surveys on Eukaryotic Genes _3 141- 160).
- the map of this vector is disclosed in Fig. 11 and the protein sequence of the mature polypeptide produced by expression of this cDNA is shown in Fig. 5.
- Oligonucleotides were synthesised on an Applied Biosystems 380B oligonucleotide synthesiser according to the manufacturer's recommendations (Applied Biosystems, Warrington, Cheshire, UK).
- An expression vector was constructed in which DNA encoding ' the HSA secretion signal and mature HSA up to and including the 387th amino acid, leucine, fused in frame to DNA encoding a segment of human fibronectin representing amino acids 585 to 1578 inclusive, was placed downstream of the hybrid promoter of EP-A-258 067 (Delta Biotechnology) , which is a highly efficient galactose- inducible promoter functional in Saccharomyces cerevisiae.
- the codon for the 1578th amino acid of human fibronectin was directly followed by a stop codon (TAA) and then the S. cerevisiae phosphoglycerate kinase (PGK) gene transcription terminator.
- TAA stop codon
- PGK phosphoglycerate kinase
- a similar vector is constructed so as to enable secretion by S. cerevisiae of a hybrid molecule representing the N-terminal 195 amino acids of HSA C- terminally fused to amino acids 585 to 1578 of human fibronectin.
- Figure 1 depicts the amino acid sequence currently thought to be the most representative of natural HSA, with (boxed) the alternative C-termini of HSA(l-n);
- Figure 2 depicts the DNA sequence coding for mature HSA, wherein the sequence included in Linker 3 is underlined;
- FIG. 3 illustrates, diagrammatically, the construction of mH0B16
- Figure 4 illustrates, diagrammatically, the construction of pH0B31
- Figure 5 (on 6 sheets) illustrates the mature protein sequence encoded by the Fn plasmid pFHDELl
- Figure 6 illustrates Linker 5, showing the eight constituent oligonucleotides
- Figure 7 shows schematically the construction of plasmid pDBDF2
- Figure 8 shows schematically the construction of plasmid pDBDF5
- Figure 9 shows schematically the construction of plasmid pDBDF9
- Figure 10 shows schematically the construction of plasmid DBDF12, using plasmid pFHDELl.
- FIG. 11 shows a map of plasmid pFHDELl.
- EXAMPLE 1 HSA 1-387 FUSED TO Fn 585-1578
- the human serum albumin coding sequence used in the construction of the following molecules is derived from the plasmid M13mpl9.7 (EP-A-201 239, Delta Biotech- nology Ltd. ) or by synthesis of oligonucleotides equivalent to parts of this sequence. Oligonucleotides were synthesised using phosphoramidite chemistry on an Applied Biosystems 380B oligonucleotide synthesizer according to the manufacturer's recommendations (AB Inc., Warrington, Cheshire, England) .
- Linker A An oligonucleotide was synthesised (Linker A) which represented a part of the known HSA coding sequence (Figure 2) from the PstI site (1235-1240, Figure 2) to the codon for valine 381 wherein that codon was changed from GTG to GTC:
- Linker 1 was ligated into the vector M13mpl9 (Norrander et al, 1983) which had been digested with PstI and Hindi and the ligation mixture was used to transfect E.coli strain XLl-Blue (Stratagene Cloning Systems, San Diego, CA) . Recombinant clones were identified by their failure to evolve a blue colour on medium containing the chromogenic indicator X-gal (5-bromo-4-chloro-3-indolyl- ⁇ - D-galactoside) in the present of IPTG (isopropylthio- ⁇ - galactoside) .
- M13mpl9.7 consists of the coding region of mature HSA in M13mpl9 (Norrander et al, 1983) such that the codon for the first amino acid of HSA, GAT, overlaps a unique Xhol site thus:
- the ligation mix was then used to transfect E.coli XL1- Blue and template DNA was prepared from several plaques and then analysed by DNA sequencing to identify a clone, pDBDl ( Figure 4), with the correct sequence.
- a 1.1 kb HindiII to PstI fragment representing the 5' end of the HSA coding region and one half of the inserted oligonucleotide linker was isolated from pDBDl by agarose gel electrophoresis. This fragment was then ligated with double stranded mHOB12 previously digested with HindiII and PstI and the ligation mix was then used to transfect E.coli XLl-Blue.
- Single stranded template DNA was prepared from mature bacteriophage particles of several plaques.
- the DNA was made double stranded in vitro by extension from annealed sequencing primer with the Klenow fragment of DNA polymerase I in the presence of deoxynucleoside triphosphates. Restriction enzyme analysis of this DNA permitted the identification of a clone with the correct configuration, mHOB15 ( Figure 4).
- Linker 3 represents from the codon for the 382nd amino acid of mature HSA (glutamate, GAA) to the codon for lysine 389 which is followed by a stop codon (TAA) and a HindiII site and then a BamHI cohesive end:
- oligonucleotides 585 to 640, Fig. 2 were prepared by synthesising six oligonucleotides (Linker 5, Fig. 6).
- the oligonucleotides 2, 3, 4, 6, 7 and 8 were phosphorylated using T4 polynucleotide kinase and then the oligonucleotides were annealed under standard conditions in pairs, i.e. 1+8, 2+7, 3+6 and 4+5.
- the annealed oligonucleotides were then mixed together and ligated with mHOB12 which had previously been digested with the restriction enzymes Hindi and EcoRI.
- pDBDFl a clone in which a linker of the expected sequence had been correctly inserted into the vector was designated pDBDFl (Fig. 7).
- This plasmid was then digested with PstI and EcoRI and -the approx. 0-24kb fragment was purified and then ligated with the 1.29kb BamHI-PstI fragment of pDBD2 (Fig. 7) and BamHI + EcoRI digested pUC19 (Yanisch-Perron, et al. , 1985) to form pDBDF2 (Fig. 7).
- pFHDELl A plasmid containing a DNA sequence encoding full length human fibronectin, pFHDELl, was digested with EcoRI and Xhol and a 0.77kb EcoRI-XhoI fragment (Fig. 8) was isolated and then ligated with EcoRI and Sail digested Ml3 mpl ⁇ (Norrander et al., 1983) to form pDBDF3 (Fig. 8).
- Linker 6 The following oligonucleotide linker (Linker 6) was synthesised, representing from the PstI site at 4784-4791 of the fibronectin sequence of EP-A-207 751 to the codon for tyrosine 1578 (Fig. 5) which is followed by a stop codon (TAA) , a HindiII site and then a BamHI cohesive end: Linker 6
- EP-A-258 067 includes the promoter of EP-A-258 067 to direct the expression of the HSA secretion signal fused to DNA encoding amino acids 1- 387 of mature HSA, in turn fused directly and in frame with DNA encoding amino acids 585-1578 of human fibronectin, after which translation would terminate at the stop codon TAA. This .is then followed by the S.cerevisiae PGK gene transcription terminator.
- the plasmid also contains sequences which permit selection and maintenance in Escherichia coli and S.cerevisiae (EP-A-258 067) .
- This plasmid was introduced into S.cerevisiae S150-2B (leu2-3 leu2-112 ura3-52 trpl-289 his3- 1) by standard procedures (Begg ⁇ , 1978). Transformants were subsequently analysed and found to produce the HSA-fibronectin fusion protein.
- the first domain of human serum albumin (amino acids 1-195) is fused to amino acids 585- 1578 of human fibronectin.
- the plasmid pDBD2 was digested with BamHI and Bglll and the 0.79kb fragment was purified and then ligated with BamHI-digested M13mpl9 to fo ' rm pDBDF6 (Fig. 6).
- a mutagenic primer was used as a mutagenic primer to create a Xhol site in pDBDF6 by in vitro mutagenesis using a kit supplied by Amersham International PLC. This site was created by changing base number 696 of HSA from a T to a G (Fig. 2). The plasmid thus formed was designated pDBDF7 (Fig. 9). The following linker was then synthesised to represent from this newly created Xhol site to the codon for lysine 195 of HSA (AAA) and then from the codon for isoleucine 585 of fibronectin to the ends of oligonucleotides 1 and 8 shown in Fig. 6.
- This linker was ligated with the annealed oligonucleotides shown in Fig. 3, i.e. 2+7, 3+6 and 4+5 together with Xhol and EcoRI digested pDBDF7 to form pDBDF ⁇ (Fig. 9). Note that in order to recreate the original HSA DNA sequence, and hence amino acid sequence, insertion of linker 7 and the other oligonucleotides into pDBDF7 does not recreate the Xhol site.
- pDBDF9 The 0.83kb BamHI-StuI fragment of pDBDF8 was purified and then was ligated with the 0.68kb EcoRI-BamHI fragment of pDBDF2 and the 2.22kb StuI-EcoRI fragment of pFHDELl into Bglll-digested pKV50 to form pDBDF9 (Fig. 9).
- This plasmid is similar to pDBDF5 except that it specifies only residues 1-195 of HSA rather than 1-387 as in pDBDF5.
- the plasmid When introduced into S.cerevisiae S150-2B as above, the plasmid directed the expression and secretion of a hybrid molecule composed of residues 1-195 of HSA fused to residues 585-1578 of fibronectin.
- This linker was then ligated with the annealed oligonucleotides shown in Fig. 6, i.e. 2+7, 3+6 and 4+5 into Hin i andEcoRI digested mH0B12, to form pDBDFlO (Fig. 7).
- the plasmid was then digested with PstI and EcoRI and the roughly 0.24kb fragment was purified and then ligated with the 1.29kb BamHI-PstI fragment of pDBD2 and BamHI and EcoRI digested pUC19 to form pDBDFll (Fig. 10) .
- the 1.5kb BamHI-StuI fragment of pDBDFll was then ligated with the 0.68kb EcoRI-BamHI fragment of pDBDF4 and the 2.22kb StuI-EcoRI fragment of pFHDELl into Bglll-diges ed pKV50 to form pDBDF12 (Fig. 10).
- This plasmid was then introduced into S.cerevisiae S150-2B.
- the purified secreted fusion protein was treated with Factor X to liberate the fibronectin fragment representing residues 585-1578 of the native molecule.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI915073A FI104255B (en) | 1989-04-29 | 1991-10-28 | Process for Preparation of Fusion Proteins Containing N-Terminal Fragments of Human Serum Albumin |
US08/153,799 US5766883A (en) | 1989-04-29 | 1993-11-17 | Polypeptides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8909916.2 | 1989-04-29 | ||
GB898909916A GB8909916D0 (en) | 1989-04-29 | 1989-04-29 | Polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990013653A1 true WO1990013653A1 (en) | 1990-11-15 |
Family
ID=10656000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1990/000650 WO1990013653A1 (en) | 1989-04-29 | 1990-04-26 | Fusion proteins containing n-terminal fragments of human serum albumin |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0470165A1 (en) |
JP (1) | JP2781459B2 (en) |
KR (1) | KR100227167B1 (en) |
AU (1) | AU630450B2 (en) |
CA (1) | CA2015687C (en) |
FI (1) | FI104255B (en) |
GB (2) | GB8909916D0 (en) |
HU (1) | HUT61049A (en) |
IE (1) | IE67651B1 (en) |
IL (1) | IL94243A (en) |
WO (1) | WO1990013653A1 (en) |
ZA (1) | ZA903237B (en) |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993015211A1 (en) * | 1992-01-31 | 1993-08-05 | Rhone-Poulenc Rorer S.A. | New polypeptides having granulocyte colony stimulating activity, preparation thereof and pharmaceutical compositions containing said polypeptides |
WO1993015199A1 (en) * | 1992-01-31 | 1993-08-05 | Rhone-Poulenc Rorer S.A. | Novel biologically active polypeptides, preparation thereof and pharmaceutical composition containing said polypeptides |
WO1994016085A2 (en) * | 1992-12-30 | 1994-07-21 | Zymogenetics, Inc. | Hybrid proteins having cross-linking and tissue-binding activities |
US5543308A (en) * | 1994-10-18 | 1996-08-06 | New England Biolabs, Inc. | Isolated DNA encoding the FSEI restriction endonuclease and related methods for producing the same |
US5610148A (en) * | 1991-01-18 | 1997-03-11 | University College London | Macroscopically oriented cell adhesion protein for wound treatment |
US5629287A (en) * | 1991-01-18 | 1997-05-13 | University College London | Depot formulations |
US5641483A (en) * | 1995-06-07 | 1997-06-24 | Beaulieu; Andre | Wound healing formulations containing human plasma fibronectin |
WO1998004718A1 (en) * | 1996-07-26 | 1998-02-05 | Novartis Ag | Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses |
US5932693A (en) * | 1996-12-10 | 1999-08-03 | Washington University | Antithrombotic peptides |
US6183989B1 (en) | 1998-01-23 | 2001-02-06 | Novo Nordisk A/S | Process for making desired polypeptides in yeast |
US6251859B1 (en) | 1995-06-07 | 2001-06-26 | BEAULIEU ANDRé | Deepithelialized skin diffusion cell system |
WO2001079444A2 (en) * | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc | Albumin fusion proteins |
US6423512B1 (en) | 1996-07-26 | 2002-07-23 | Novartis Ag | Fusion polypeptides |
US6548653B1 (en) | 1998-06-15 | 2003-04-15 | Genzyme Transgenics Corporation | Erythropoietin analog-human serum albumin fusion |
EP1666589A1 (en) * | 2003-08-22 | 2006-06-07 | Takara Bio Inc. | Process for producing cytotoxic lymphocytes |
WO2006067511A1 (en) | 2004-12-23 | 2006-06-29 | Novozymes Delta Limited | Gene expression technique |
EP2048236A1 (en) | 2003-12-23 | 2009-04-15 | Novozymes Biopharma DK A/S | Gene expression technique |
WO2010092135A2 (en) | 2009-02-11 | 2010-08-19 | Novozymes Biopharma Uk Ltd. | Albumin variants and conjugates |
US7910368B2 (en) | 2001-08-15 | 2011-03-22 | Takara Bio Inc. | Method of extended culture for antigen-specific cytotoxic lymphocytes |
US8252551B2 (en) | 2003-12-23 | 2012-08-28 | Novozymes Biopharma Dk A/S | 2-micron family plasmid and use thereof |
US8334365B2 (en) | 2006-06-07 | 2012-12-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8728811B2 (en) | 2002-03-25 | 2014-05-20 | Takara Bio Inc. | Process for producing cytotoxic lymphocyte |
US8765915B2 (en) | 2006-02-06 | 2014-07-01 | Csl Behring Gmbh | Modified coagulation factor VIIa with extended half-life |
WO2014165093A2 (en) | 2013-03-13 | 2014-10-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
US8993517B2 (en) | 2001-12-21 | 2015-03-31 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9139611B2 (en) | 2006-07-13 | 2015-09-22 | Novozymes Biopharma Dk A/S | Process for preparing particles of proteinaceous material |
US9944691B2 (en) | 2012-03-16 | 2018-04-17 | Albumedix A/S | Albumin variants |
US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
US10501524B2 (en) | 2012-11-08 | 2019-12-10 | Albumedix Ltd | Albumin variants |
US10633428B2 (en) | 2015-08-20 | 2020-04-28 | Albumedix Ltd | Albumin variants and conjugates |
US10696732B2 (en) | 2009-10-30 | 2020-06-30 | Albumedix, Ltd | Albumin variants |
US10711050B2 (en) | 2011-11-18 | 2020-07-14 | Albumedix Ltd | Variant serum albumin with improved half-life and other properties |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9408466D0 (en) * | 1994-04-27 | 1994-06-22 | Univ Nottingham | Cloning and functional expression of neurotoxins |
EP3192872A1 (en) | 2003-08-26 | 2017-07-19 | The Regents of the University of Colorado, a body corporate | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
KR102103476B1 (en) * | 2011-06-24 | 2020-04-23 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
CN110461880A (en) | 2016-11-10 | 2019-11-15 | 科乐斯疗法公司 | GDNF fused polypeptide and its application method |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0308381A1 (en) * | 1987-09-14 | 1989-03-22 | Skandigen Ab | Artificial gene coding for authentic human serum albumin, use thereof, and method of producing the same |
EP0322094A1 (en) * | 1987-10-30 | 1989-06-28 | Delta Biotechnology Limited | N-terminal fragments of human serum albumin |
-
1989
- 1989-04-29 GB GB898909916A patent/GB8909916D0/en active Pending
-
1990
- 1990-04-26 EP EP90907285A patent/EP0470165A1/en active Pending
- 1990-04-26 WO PCT/GB1990/000650 patent/WO1990013653A1/en active IP Right Grant
- 1990-04-26 JP JP2506978A patent/JP2781459B2/en not_active Expired - Lifetime
- 1990-04-26 AU AU55646/90A patent/AU630450B2/en not_active Expired
- 1990-04-26 HU HU904413A patent/HUT61049A/en unknown
- 1990-04-27 IE IE155490A patent/IE67651B1/en not_active IP Right Cessation
- 1990-04-27 ZA ZA903237A patent/ZA903237B/en unknown
- 1990-04-27 CA CA002015687A patent/CA2015687C/en not_active Expired - Lifetime
- 1990-04-29 IL IL9424390A patent/IL94243A/en not_active IP Right Cessation
-
1991
- 1991-09-06 GB GB9119043A patent/GB2246783B/en not_active Expired - Lifetime
- 1991-10-14 KR KR1019910701334A patent/KR100227167B1/en not_active IP Right Cessation
- 1991-10-28 FI FI915073A patent/FI104255B/en active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0308381A1 (en) * | 1987-09-14 | 1989-03-22 | Skandigen Ab | Artificial gene coding for authentic human serum albumin, use thereof, and method of producing the same |
EP0322094A1 (en) * | 1987-10-30 | 1989-06-28 | Delta Biotechnology Limited | N-terminal fragments of human serum albumin |
Cited By (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5610148A (en) * | 1991-01-18 | 1997-03-11 | University College London | Macroscopically oriented cell adhesion protein for wound treatment |
US5629287A (en) * | 1991-01-18 | 1997-05-13 | University College London | Depot formulations |
US5665863A (en) * | 1992-01-31 | 1997-09-09 | Rhone-Poulenc Rorer S.A. | Polypeptides having granulocyte colony stimulating activity, their preparation and pharmaceutical compositions containing them |
WO1993015199A1 (en) * | 1992-01-31 | 1993-08-05 | Rhone-Poulenc Rorer S.A. | Novel biologically active polypeptides, preparation thereof and pharmaceutical composition containing said polypeptides |
FR2686899A1 (en) * | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
FR2686900A1 (en) * | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
EP1449921A2 (en) * | 1992-01-31 | 2004-08-25 | Aventis Pharma S.A. | Novel biologically active polypeptides, preparation thereof and pharmaceutical composition containing said polypeptides |
EP1449921A3 (en) * | 1992-01-31 | 2006-01-11 | Delta Biotechnology Limited | Novel biologically active polypeptides, preparation thereof and pharmaceutical composition containing said polypeptides |
WO1993015211A1 (en) * | 1992-01-31 | 1993-08-05 | Rhone-Poulenc Rorer S.A. | New polypeptides having granulocyte colony stimulating activity, preparation thereof and pharmaceutical compositions containing said polypeptides |
US5876969A (en) * | 1992-01-31 | 1999-03-02 | Fleer; Reinhard | Fusion polypeptides comprising human serum albumin, nucleic acids encoding same, and recombinant expression thereof |
US5830700A (en) * | 1992-12-30 | 1998-11-03 | Irani; Meher | Hybrid proteins having cross-linking and tissue-binding activities |
WO1994016085A2 (en) * | 1992-12-30 | 1994-07-21 | Zymogenetics, Inc. | Hybrid proteins having cross-linking and tissue-binding activities |
WO1994016085A3 (en) * | 1992-12-30 | 1994-12-22 | Zymogenetics Inc | Hybrid proteins having cross-linking and tissue-binding activities |
US5543308A (en) * | 1994-10-18 | 1996-08-06 | New England Biolabs, Inc. | Isolated DNA encoding the FSEI restriction endonuclease and related methods for producing the same |
US6251859B1 (en) | 1995-06-07 | 2001-06-26 | BEAULIEU ANDRé | Deepithelialized skin diffusion cell system |
US5641483A (en) * | 1995-06-07 | 1997-06-24 | Beaulieu; Andre | Wound healing formulations containing human plasma fibronectin |
US6423512B1 (en) | 1996-07-26 | 2002-07-23 | Novartis Ag | Fusion polypeptides |
CZ297634B6 (en) * | 1996-07-26 | 2007-02-21 | Novartis Ag | Fusion polypeptides comprising IgE and HAS, process of their preparation, pharmaceutical composition in which the fusion polypeptides are comprised as well as their use |
WO1998004718A1 (en) * | 1996-07-26 | 1998-02-05 | Novartis Ag | Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses |
US6083914A (en) * | 1996-12-10 | 2000-07-04 | Washington University | Antithrombotic peptides |
US5932693A (en) * | 1996-12-10 | 1999-08-03 | Washington University | Antithrombotic peptides |
US6183989B1 (en) | 1998-01-23 | 2001-02-06 | Novo Nordisk A/S | Process for making desired polypeptides in yeast |
US7101971B2 (en) | 1998-06-15 | 2006-09-05 | Gtc Biotherapeutics, Inc. | Erythropoietin analog-human serum albumin fusion |
US6548653B1 (en) | 1998-06-15 | 2003-04-15 | Genzyme Transgenics Corporation | Erythropoietin analog-human serum albumin fusion |
EP1276856A1 (en) * | 2000-04-12 | 2003-01-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9821039B2 (en) | 2000-04-12 | 2017-11-21 | Albumedix A/S | Albumin fusion proteins |
EP1274719A4 (en) * | 2000-04-12 | 2004-05-19 | Human Genome Sciences Inc | Albumin fusion proteins |
EP1276856A4 (en) * | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | Albumin fusion proteins |
EP1276849A4 (en) * | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | Albumin fusion proteins |
EP1276756A4 (en) * | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | Albumin fusion proteins |
EP1276849A2 (en) * | 2000-04-12 | 2003-01-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8946156B2 (en) | 2000-04-12 | 2015-02-03 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
US9849162B2 (en) | 2000-04-12 | 2017-12-26 | Albumedix A/S | Treatment with factor VII-albumin fusion protein |
EP1276756A1 (en) * | 2000-04-12 | 2003-01-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1274719A2 (en) * | 2000-04-12 | 2003-01-15 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2001079444A2 (en) * | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc | Albumin fusion proteins |
WO2001079444A3 (en) * | 2000-04-12 | 2002-05-23 | Human Genome Sciences Inc | Albumin fusion proteins |
EP1832599A2 (en) * | 2000-04-12 | 2007-09-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1832599A3 (en) * | 2000-04-12 | 2007-11-21 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7785599B2 (en) | 2000-04-12 | 2010-08-31 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7910368B2 (en) | 2001-08-15 | 2011-03-22 | Takara Bio Inc. | Method of extended culture for antigen-specific cytotoxic lymphocytes |
US8993517B2 (en) | 2001-12-21 | 2015-03-31 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9221896B2 (en) | 2001-12-21 | 2015-12-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9296809B2 (en) | 2001-12-21 | 2016-03-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8975070B2 (en) | 2002-03-25 | 2015-03-10 | Takara Bio Inc. | Process for producing cytotoxic lymphocyte |
US8728811B2 (en) | 2002-03-25 | 2014-05-20 | Takara Bio Inc. | Process for producing cytotoxic lymphocyte |
US8927273B2 (en) | 2003-08-22 | 2015-01-06 | Takara Bio Inc. | Process for producing cytotoxic lymphocytes |
EP1666589A1 (en) * | 2003-08-22 | 2006-06-07 | Takara Bio Inc. | Process for producing cytotoxic lymphocytes |
EP1666589A4 (en) * | 2003-08-22 | 2006-10-04 | Takara Bio Inc | Process for producing cytotoxic lymphocytes |
US8969064B2 (en) | 2003-12-23 | 2015-03-03 | Novozymes Biopharma Dk A/S | Gene expression technique |
US9057061B2 (en) | 2003-12-23 | 2015-06-16 | Novozymes Biopharma Dk A/S | Gene expression technique |
US8252551B2 (en) | 2003-12-23 | 2012-08-28 | Novozymes Biopharma Dk A/S | 2-micron family plasmid and use thereof |
EP2048236A1 (en) | 2003-12-23 | 2009-04-15 | Novozymes Biopharma DK A/S | Gene expression technique |
WO2006067511A1 (en) | 2004-12-23 | 2006-06-29 | Novozymes Delta Limited | Gene expression technique |
EP2330200A2 (en) | 2004-12-23 | 2011-06-08 | Novozymes Biopharma DK A/S | Gene expression technique |
US8765915B2 (en) | 2006-02-06 | 2014-07-01 | Csl Behring Gmbh | Modified coagulation factor VIIa with extended half-life |
US8334365B2 (en) | 2006-06-07 | 2012-12-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9139611B2 (en) | 2006-07-13 | 2015-09-22 | Novozymes Biopharma Dk A/S | Process for preparing particles of proteinaceous material |
US9493545B2 (en) | 2009-02-11 | 2016-11-15 | Albumedix A/S | Albumin variants and conjugates |
EP3243835A1 (en) | 2009-02-11 | 2017-11-15 | Albumedix A/S | Albumin variants and conjugates |
US11555061B2 (en) | 2009-02-11 | 2023-01-17 | Albumedix, Ltd | Albumin variants and conjugates |
WO2010092135A2 (en) | 2009-02-11 | 2010-08-19 | Novozymes Biopharma Uk Ltd. | Albumin variants and conjugates |
US10696732B2 (en) | 2009-10-30 | 2020-06-30 | Albumedix, Ltd | Albumin variants |
US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
US10711050B2 (en) | 2011-11-18 | 2020-07-14 | Albumedix Ltd | Variant serum albumin with improved half-life and other properties |
US10329340B2 (en) | 2012-03-16 | 2019-06-25 | Albumedix Ltd | Albumin variants |
US9944691B2 (en) | 2012-03-16 | 2018-04-17 | Albumedix A/S | Albumin variants |
US10501524B2 (en) | 2012-11-08 | 2019-12-10 | Albumedix Ltd | Albumin variants |
US10934341B2 (en) | 2012-11-08 | 2021-03-02 | Albumedix, Ltd. | Albumin variants |
WO2014165093A2 (en) | 2013-03-13 | 2014-10-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
US10633428B2 (en) | 2015-08-20 | 2020-04-28 | Albumedix Ltd | Albumin variants and conjugates |
Also Published As
Publication number | Publication date |
---|---|
GB8909916D0 (en) | 1989-06-14 |
IE901554L (en) | 1990-10-29 |
GB2246783B (en) | 1992-10-14 |
JP2781459B2 (en) | 1998-07-30 |
EP0470165A1 (en) | 1992-02-12 |
AU630450B2 (en) | 1992-10-29 |
HUT61049A (en) | 1992-11-30 |
GB9119043D0 (en) | 1991-12-04 |
IL94243A (en) | 1995-10-31 |
KR100227167B1 (en) | 1999-10-15 |
FI104255B1 (en) | 1999-12-15 |
GB2246783A (en) | 1992-02-12 |
HU904413D0 (en) | 1992-01-28 |
IE67651B1 (en) | 1996-04-17 |
KR920701451A (en) | 1992-08-11 |
IL94243A0 (en) | 1991-01-31 |
CA2015687C (en) | 2000-08-29 |
ZA903237B (en) | 1991-03-27 |
FI104255B (en) | 1999-12-15 |
CA2015687A1 (en) | 1990-10-29 |
FI915073A0 (en) | 1991-10-28 |
AU5564690A (en) | 1990-11-29 |
JPH04506598A (en) | 1992-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2015687C (en) | Human serum albomin fusion polypeptide | |
EP0399666B1 (en) | Fusion proteins containing n-terminal fragments of human serum albumin | |
US5766883A (en) | Polypeptides | |
JP2708518B2 (en) | Synthetic yeast leader peptide | |
US4766073A (en) | Expression of biologically active PDGF analogs in eucaryotic cells | |
FI104564B (en) | Peptide and DNA sequences | |
US5187263A (en) | Expression of biologically active PDGE analogs in eucaryotic cells | |
JP2791418B2 (en) | Method for producing heterologous protein, recombinant DNA, transformant | |
PT99848A (en) | PROCESS FOR THE PREPARATION OF SYNTHETIC LEADER SEQUENCES | |
US20070010439A1 (en) | Production of human parathyroid hormone from microorganisms | |
US5705484A (en) | Biologically active polypeptide fusion dimers | |
EP0338634B1 (en) | Viper venom polypeptides and genetic expression | |
JPH01240191A (en) | Novel signal peptide functioning by yeast and secretory manifestation of foreign protein using same | |
AU665034B2 (en) | Production of human parathyroid hormone from microorganisms | |
EP0129073B1 (en) | Hybrid dna synthesis of mature growth hormone releasing factor | |
IL88925A (en) | Hirudin derivative and pharmaceutical composition containing same | |
ES2242969T3 (en) | VECTOR FOR THE EXPRESSION OF PROTEINS WITH N-TERMINAL PROLONGATION IN LIFTING CELLS. | |
US5656458A (en) | Expression and processing of amino terminus acetylated FGF's in yeast | |
JP2840441B2 (en) | Expression and processing of authentic FGF in yeast | |
IE62522B1 (en) | A process for the preparation of foreign proteins in streptomycetes | |
KR20040019361A (en) | Method for making acylated polypeptides | |
AU641816B2 (en) | Expression of biologically active PDGF analogs in eucaryotic cells | |
PT716705E (en) | PROCESS FOR THE PREPARATION BY RECOMBINATION OF PROTEINS IN HANSENULA YEAST | |
CA1340264C (en) | Recombinant dna expression of novel diuretic/vasodilator compounds | |
WO2002031178A1 (en) | An artificial gene and vectors for expressing high-yield recombinant ovine interferon-tau in pichia pastoris |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU FI GB HU JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1990907285 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 915073 Country of ref document: FI |
|
WWP | Wipo information: published in national office |
Ref document number: 1990907285 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1990907285 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 915073 Country of ref document: FI |